Clinevo Technologies | Clinical Research & Healthcare Technology Solutions

  The pharmacovigilance software market was valued at approximately USD 2.09 billion in 2025 and is projected to reach USD 5.06 billion by 2035, growing at a CAGR of 9.24%. That growth reflects a genuine operational shift, not a commercial trend. Regulatory reporting obligations have expanded across every major jurisdiction. Case volumes have grown steadily. And the expectation that safety teams will process and submit high-quality ICSRs within tight timeframes has become firmly established across the FDA, EMA, PMDA, and MHRA. The decision to invest in PV software is, therefore, rarely about whether to act. It is about which platform to select, how to evaluate it against your organization’s operational reality, and how to avoid the implementation pitfalls that can derail even well-planned programs. This guide is written for decision-makers actively evaluating pharmacovigilance software platforms in 2026, and who need a structured way to separate vendor marketing from operational ...

 The common perception of pharmacovigilance database migration is simple: move data from the legacy system, validate it during a transition phase, and deploy it into the new platform. Project timelines are typically estimated at three to six months, depending on portfolio size and complexity. However, organizations often discover that managing historical ICSR data introduces operational and compliance challenges that significantly increase effort beyond the initial plan. READ MORE

  Most pharmacovigilance (PV) teams treat duplicate literature records as an operational nuisance. A few cases get merged, a few line listings get cleaned up, and the case backlog moves forward. The problem is that this view holds only until an inspector starts asking why the same patient case appears as three separate ICSRs in your safety database, or why your signal counts for a specific product look inflated against EudraVigilance reference data. At that point, duplicate literature records stop being a housekeeping issue and become a data integrity finding. The European Medicines Agency itself acknowledges the scale of the problem. Its Medical Literature Monitoring (MLM) service was created specifically to “avoid duplication of effort by marketing authorisation holders” and to “prevent the same reports being entered into databases by multiple marketing authorisation holders” for substances with many authorisations across the EEA. When a regulator builds an entire centralised s...